A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

NCT05622058 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study has been terminated early given that the first four patients enrolled have experienced Grade 4 neutropenia and alopecia after cycle 1 and as such failed to meet the primary endpoint and the main secondary endpoint.

Conditions

Prevention of Chemotherapy-induced Myelosuppression

Interventions

DRUG: ALRN-6924
DRUG: TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)

Sponsor

Aileron Therapeutics, Inc.